Faisability and Efficacity of the Reinforced Communautary Support Program (PARC) on the Complications of Chemsex
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 20, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a program called the Parcours d'Accompagnement Renforcé Communautaire (PARC), which aims to help individuals who are involved in chemsex—an activity where people use drugs while engaging in sexual activities. The program is designed for men who have sex with men (MSM), and trans or non-binary individuals who are part of gay hookup networks and have a history of using specific drugs like methamphetamine or GBL. The goal is to provide support that reduces addiction symptoms, improves mental health, and enhances overall quality of life.
To be eligible for the trial, participants must be engaging in chemsex and looking to reduce or stop their drug use. They should be willing to share information for the study and have no uncontrolled medical or mental health issues that could interfere. Those who join can expect to participate in workshops and consultations over several months, focusing on building social connections, improving self-esteem, and finding a healthier lifestyle. Throughout the study, researchers will gather feedback to see how well the program works and how it can be improved for future use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • MSM and/or non-binary individuals, trans men or women associated with gay sexual networks
- • Engaging in chemsex (as defined by the European Chemsex Forum and having consumed at least twice a cathinone and/or methamphetamine and/or GHB/GBL)
- • Seeking care for chemsex
- • Referred to the PARC program with the goal of reducing or stopping consumption
- • Not opposed to data collection for this study
- • Uncontrolled somatic or psychiatric conditions
- Exclusion Criteria:
- • Refusal to participate
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Michel OHAYON, MD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported